Published in Medicine and Law Weekly, October 15th, 2004
Financial terms of the agreement were not disclosed.
"We are pleased to have worked with InterMune to reach this agreement," said Ursula Bartels, Chiron's general counsel. "Making our HCV technology available to develop small-molecule therapeutics will help to address the toll from this terrible disease. Chiron is committed to meeting this major medical need, both through its broad licensing policy and through its own small-molecule therapeutic program."
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medicine and Law Weekly